Full recovery over one year of the overlap syndrome scleromyositis to maintenance therapy with mycophenolate mofetil and rituximab, which relapsed within 8 months of discontinuation

Scleromyositis (SM) is a rare and poorly understood condition that combines features of systemic sclerosis and immune-mediated myositis, often linked to anti-PM-scleroderma antibodies.Despite efforts to classify SM, it demonstrates unique clinical patterns that distinguish it from other myositis subtypes.The management of SM remains challenging, as there are no established guidelines or standardised treatment protocols.